Medical Policy:
Ocular Photoscreening
(Commercial)

<table>
<thead>
<tr>
<th>POLICY NUMBER</th>
<th>EFFECTIVE DATE</th>
<th>APPROVED BY</th>
</tr>
</thead>
<tbody>
<tr>
<td>M20190008</td>
<td>9/01/2019</td>
<td>MPC (Medical Policy Committee)</td>
</tr>
</tbody>
</table>

**IMPORTANT NOTE ABOUT THIS MEDICAL POLICY:**

Property of ConnectiCare, Inc. All rights reserved. The treating physician or primary care provider must submit to ConnectiCare, Inc. the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, ConnectiCare will not be able to properly review the request for prior authorization. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. The clinical review criteria expressed below reflects how ConnectiCare determines whether certain services or supplies are medically necessary. ConnectiCare established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). ConnectiCare, Inc. expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. Each benefit plan defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by ConnectiCare, as some plans exclude coverage for services or supplies that ConnectiCare considers medically necessary. If there is a discrepancy between this guideline and a member's benefits plan, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of the State of CT and/or the Federal Government. Coverage may also differ for our Medicare members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including including National Coverage Determinations (NCD), Local Coverage Determinations (LCD) and/or Local Medical Review Policies (LMRP). All coding and website links are accurate at time of publication.

**Guidelines:**

**Instrument-based ocular screening using photoscreening is covered as medically necessary for vision screening for the following:**

- As a preventive screening instrument for children 1 - 3 years of age (ends on 4th birthday).
- Individuals 4 years of age and older who are developmentally delayed and are unable or unwilling to cooperate with routine visual acuity screening.

**Limitations/Exclusions:**

Instrument-based ocular screening using photoscreening is unproven and not medically necessary for all other patient populations including children younger than 1 year of age. More age-appropriate screening methods are available for these populations.
**Medical Policy:**
**Ocular Photoscreening (Commercial)**

**Applicable CPT and Diagnosis Codes**

- **99174** Instrument-based ocular screening (e.g., photoscreening, automated refraction), bilateral; with remote analysis and report
- **99177** Instrument-based ocular screening (e.g., photoscreening, automated refraction), bilateral; with on-site analysis

**Clinical Evidence**

Ocular photoscreening has been investigated as an alternative screening method to detect risk factors for amblyopia, which include strabismus, high refractive errors, anisometropia, and media opacities. Many children permanently lose vision each year as a result of these treatable ocular disease processes. Early diagnosis and treatment of these conditions has been shown to yield better visual outcomes.

The U.S. Preventive Services Task Force (USPSTF, 2017) recommended vision screening for amblyopia and its risk factors in children aged 3 to 5 years. Evidence was insufficient to assess the benefits and harms of vision screening in children younger than 3 years. Various screening tests are used in primary care to identify visual impairment among children, including visual acuity tests, stereoacuity tests, the cover-uncover test, and the Hirschberg light reflex test (for ocular alignment/strabismus). Photoscreeners (instruments that detect amblyogenic risk factors and refractive errors) may also be used.

Infants and young preverbal children are difficult to screen because they are unable to provide subjective responses to visual acuity testing and do not easily cooperate with testing of ocular alignment or stereoacuity (AAP, 2002). For similar reasons, it also is difficult to screen certain older children, such as those who are nonverbal or have developmental delays.

Ocular photoscreening has been used to screen for amblyogenic factors, such as strabismus, media opacities, and significant refractive errors, in children (AAP, 2002). An advantage of ocular photoscreening over standard methods of testing visual acuity, ocular alignment and stereoacuity is that photoscreening requires little cooperation from the child, other than having to fixate on the appropriate target long enough for photoscreening. Thus, photoscreening has the potential to improve vision screening rates in preverbal children and those with developmental delays who are the most difficult to screen. Many of the children that are most difficult to screen using conventional methods are also at highest risk of amblyopia (e.g., premature infants, children with developmental delays).

In a retrospective study, Longmuir et al. (2013) reported their experience with vision screening in children and compared the results of photoscreening in children younger than 3 years with those of children of preschool age and older. During the 11 years of the study, 210,695 photoscreens on children were performed at 13,750 sites. According to the authors, these results confirm that early screening, before amblyopia is more pronounced, can reliably detect amblyogenic risk factors in children younger than 3 years of age, and they recommend initiation of photoscreening in children aged 1 year and older.

In a cross-sectional study, Longmuir et al. (2010) reported on a cohort of preschool children screened by a photoscreening program (using MTI PhotoScreeener) over a 9-year period from a single, statewide vision screening effort. Children who failed the photoscreening were referred to local eye care professionals who performed a comprehensive eye evaluation. Over the 9 years of the continuously operating program, 147,809 children underwent photoscreens to detect
amblyopic risk factors at 9,746 sites. Because of abnormal photoscreen results, 6,247 children (4.2%) were referred. The overall positive predictive value (PPV) of the MTI PhotoScreener was 94.2%.

Professional Societies:

**American Academy of Ophthalmology (AAO)**
The American Academy of Ophthalmology (AAO) Preferred Practice Patterns for Pediatric Eye Evaluations (2017) state that vision screening should be performed at an early age and at regular intervals throughout childhood. The elements of vision screening vary depending on the age and level of cooperation of the child. Subjective visual acuity testing is preferred to instrument-based screening in children who are able to participate reliably. Instrument-based screening is useful for some young children and those with developmental delays. Instrument-based screening techniques, such as photoscreening and autorefraction, are useful for assessing amblyopia and reduced-vision risk factors for children ages 1 to 5 years, as this is a critical time for visual development. Instrument-based screening can occur for children at age 6 years and older when children cannot participate in optotype-based screening.

**American Academy of Ophthalmology/ American Association for Pediatric Ophthalmology and Strabismus / American Association of Certified Orthoptists**
The American Academy of Ophthalmology, the American Association for Pediatric Ophthalmology and Strabismus, and the American Association of Certified Orthoptists coauthored a policy statement regarding the use of instrument-based screening devices. These devices are available commercially and have had extensive validation, both in field studies as well as in the pediatrician’s offices. Screening instruments detect amblyopia, high refractive error, and strabismus, which are the most common conditions producing visual impairment in children. If available, they can be used at any age but have better success after 18 months of age. Instrument-based screening can be repeated at each annual preventive medicine encounter through 5 years of age or until visual acuity can be assessed reliably using optotypes. Using these techniques in children younger than 6 years can enhance detection of conditions that may lead to amblyopia and/or strabismus compared with traditional methods of assessment (Donahue and Baker, 2016).

**References:**


Medical Policy: Ocular Photoscreening (Commercial)


Revision history

<table>
<thead>
<tr>
<th>DATE</th>
<th>REVISION</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/2019</td>
<td>• New Policy</td>
</tr>
</tbody>
</table>